Posted: 6 October 2025
Snoretox has won the Emerging Company Innovation Award at the global Veterinarian new products conference KCAnimalHealth Summit in the USA. This convention is the leading deal-making convention for veterinary pharmaceutical companies in the USA, attended by veterinary pharmaceutical companies along with the new products seeking deals. The highly credentialed judges selected Snoretox unanimously from the 41 applicants. This award was made after a presentation about their muscle-targeted neuromuscular stimulant drug in dogs suffering from BOAS Syndrome, where the drug is injected into the muscles in the floor of the mouth. Snoretox continues to attract a high level of interest, and new opportunities are opening up. This award has both supported this momentum and added value to the company.
Find out more here.
